Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Debt Ratio: 2014-2025

Historic Debt Ratio for ImmunityBio (IBRX) over the last 11 years, with Sep 2025 value amounting to 0.61.

  • ImmunityBio's Debt Ratio fell 18.85% to 0.61 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.61, marking a year-over-year decrease of 18.85%. This contributed to the annual value of 0.74 for FY2024, which is 141.07% up from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Debt Ratio is 0.61, which was down 20.23% from 0.76 recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Debt Ratio peaked at 1.50 during Q1 2021, and registered a low of 0.31 during Q4 2023.
  • Moreover, its 3-year median value for Debt Ratio was 0.73 (2023), whereas its average is 0.70.
  • Per our database at Business Quant, ImmunityBio's Debt Ratio spiked by 22,305.32% in 2021 and then plummeted by 47.21% in 2022.
  • Over the past 5 years, ImmunityBio's Debt Ratio (Quarterly) stood at 0.65 in 2021, then decreased by 27.30% to 1.06 in 2022, then increased by 4.96% to 0.31 in 2023, then skyrocketed by 141.07% to 0.74 in 2024, then decreased by 18.85% to 0.61 in 2025.
  • Its last three reported values are 0.61 in Q3 2025, 0.76 for Q2 2025, and 0.98 during Q1 2025.